Evidence Explorer · MS-N305 · Enzyme supplements · Supportive care · Appraised 11 November 2026
A multicenter triple-blind phase III trial found that the Wobe-Mugos E proteolytic-enzyme mixture did not reduce oral mucositis during head-and-neck radiotherapy.
Evidence at a glance
- Evidence label: Phase III negative evidence
- Benefit: No reduction in maximum mucositis; average scores over weeks 1–6 favored placebo because mucositis began earlier in the enzyme group.
- Certainty: Moderate for no meaningful benefit from this exact mixture in the studied radiotherapy setting.
- Risk: The trial product was reported as tolerated, but papain and pancreatic enzymes can cause gastrointestinal symptoms or allergy; bleeding and medicine interactions require review.
- Goal: Prevention of radiotherapy-related oral mucositis; not cancer control.
What was studied
Formulation: Wobe-Mugos E contained papain 100 mg, trypsin 40 mg and chymotrypsin 40 mg per studied unit; the accessible abstract did not verify the exact daily capsule count for this head-and-neck trial.
Design: Sixty-nine people with oral-cavity or oropharyngeal cancer entered a prospective multicenter randomized placebo-controlled triple-blind phase III trial; 61 were analyzed.
Results: Maximum mucositis did not differ. Average mucositis scores across weeks 1–6 significantly favored placebo, attributed to earlier onset in the enzyme arm. Other older radiotherapy trials reported mixed findings in different sites.
What this evidence cannot establish
This exact negative trial does not establish benefit for oral mucositis, and results from pelvic or cervical radiotherapy cannot be assumed to apply to the mouth.
The evidence does not support proteolytic enzymes as anticancer treatment.
Safety and practical context
Papain can provoke allergic reactions, especially in people with papaya or latex sensitivity. Oral enzyme mixtures may cause nausea, diarrhea or abdominal symptoms.
Because proteolytic products differ and may affect bleeding or other medicines, review the exact formulation with the oncology pharmacist.
Questions for the care team
- Is this the same enzyme mixture studied in the phase III trial?
- Could papaya/latex allergy or bleeding risk make the product unsafe?
- What guideline-supported oral-care and mucositis measures are available?
Sources and identifiers
- Triple-blind phase III trial (PMID 17340069)
- Older head-and-neck trial (PMID 10921218)
- Negative pelvic-radiotherapy trial (PMID 12413670)
- MASCC/ISOO mucositis guideline update (PMID 34714510)
Funding and conflicts: Funding and conflicts were not verified from full text; the primary source was appraised at abstract level.
Source access: Original reports, abstracts/full text where available, registries and authoritative safety sources checked 11 November 2026. The phase III head-and-neck report was available as an abstract; unsupported details were omitted.
This educational evidence record is not a personal treatment recommendation. Symptom or toxicity findings do not establish tumor response, delayed recurrence or longer survival; laboratory and animal findings are not proof of clinical benefit.
